Payment overview · 2025
General Payments
$4,785.71
18 reported records · 11 companies
Healthcare provider profile · identity verified
Gregory Lawton Eaves, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · AIKEN, SC · NPI 1487737821
Verified facts
What the public records show
CMS Open Payments records show Gregory Lawton Eaves, M.D. received $4,785.71 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 90.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $4,337.12 | 90.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$68.71 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.80 | 1.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.29 | 1.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.26 | 0.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.43 | 0.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.38 | 0.4% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.90 | 0.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $16.58 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.24 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,337.12 | 2 |
| Food and Beverage | $448.59 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $4,337.12 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $68.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $56.80 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.26 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 305 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
305 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 773 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 405 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 99 |
| Carvedilol | Carvedilol | 312 | 88 |
| Entresto | Sacubitril/Valsartan | 305 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 249 | 73 |
| Nebivolol Hcl | Nebivolol Hcl | 187 | 52 |
| Spironolactone | Spironolactone | 180 | 55 |
| Xarelto | Rivaroxaban | 177 | 41 |
| Furosemide | Furosemide | 173 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 55 |
| Lisinopril | Lisinopril | 170 | 59 |
| Losartan Potassium | Losartan Potassium | 149 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 50 |
| Progesterone | Progesterone, Micronized | 132 | 40 |
| Ozempic | Semaglutide | 127 | 22 |
| Valsartan | Valsartan | 125 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 106 | 35 |
| Estradiol (Twice Weekly) | Estradiol | 102 | 25 |
| Liothyronine Sodium | Liothyronine Sodium | 100 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 29 |
| Nifedipine Er | Nifedipine | 91 | 27 |
| Ranolazine Er | Ranolazine | 90 | 21 |
| Farxiga | Dapagliflozin Propanediol | 88 | 16 |
| Potassium Chloride | Potassium Chloride | 83 | 22 |
| Simvastatin | Simvastatin | 81 | 26 |
| Famotidine | Famotidine | 77 | 33 |
| Torsemide | Torsemide | 76 | 21 |
| Warfarin Sodium | Warfarin Sodium | 76 | 21 |
| Sotalol | Sotalol Hcl | 72 | 22 |
| Jardiance | Empagliflozin | 67 | 16 |
| Flecainide Acetate | Flecainide Acetate | 65 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 19 |
| Metformin Hcl | Metformin Hcl | 62 | 19 |
| Atenolol | Atenolol | 61 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Multaq | Dronedarone Hcl | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 42 | 11 |
| Digoxin | Digoxin | 39 | 11 |
| Tiadylt Er | Diltiazem Hcl | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Repatha Pushtronex | Evolocumab | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Niacin Er | Niacin | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | 13 |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Mercaptopurine | Mercaptopurine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,785.71 · 18 records | Novo Nordisk Inc | ACTIV.A.C., AURORA EV-ICD MRI SURESCAN, DIAMONDBACK CORONARY, ENTRESTO, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, Ozempic, PROMOGRAN PRISMA, Tlando, VERQUVO, WAINUA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error